行情

ALDX

ALDX

Aldeyra
NASDAQ

实时行情|Nasdaq Last Sale

7.68
-0.24
-3.03%
休市 16:00 11/26 EST
开盘
8.25
昨收
7.92
最高
8.25
最低
7.32
成交量
69.33万
成交额
--
52周最高
15.95
52周最低
6.47
市值
4.46亿
市盈率(TTM)
-7.0666
分时
5日
1月
3月
1年
5年
Implied Volatility Surging for Aldeyra (ALDX) Stock Options
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Zacks · 11/11 13:38
Aldeyra Therapeutics to Participate in Upcoming Conferences
LEXINGTON, Mass., November 09, 2021--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., P...
Business Wire · 11/09 21:05
Aldeyra Therapeutics Completes Enrollment in Dry Eye Disease Phase 3 Trial
MT Newswires · 11/09 15:35
BRIEF-Aldeyra Therapeutics Completes Enrollment In Phase 3 Trial In Patients With Dry Eye Disease
reuters.com · 11/09 13:08
HealthInvest Partners AB Buys Harmony Biosciences Holdings Inc, Rigel Pharmaceuticals Inc, ...
GuruFocus News · 11/08 13:38
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease.
Benzinga · 11/02 16:44
Aldeyra Therapeutics shares slide 18% after mid-stage reproxalap dry eye disease trial results
Aldeyra Therapeutics (NASDAQ:ALDX) shares slide more than 18% premarket after the company posted results from its mid-stage trial of reproxalap in patients with dry eye disease. The trial enrolled 158 patients: 80 patients
Seekingalpha · 11/02 12:16
BRIEF-Aldeyra Therapeutics Announces Achievement Of Primary Endpoint Of Ocular Redness In Mid-Stage Study In Dry Eye Disease
reuters.com · 11/02 12:06
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ALDX最新的财务预测,通过ALDX每股收益,每股净资产,每股现金流等数据分析Aldeyra近期的经营情况,然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ALDX价格均价为25.60,最高价位32.00,最低价为16.00。
最高32.00
均价25.60
最低16.00
现价7.68
EPS
实际EPS
预期EPS
-0.24-0.18-0.12-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 152
机构持股: 4,264.82万
持股比例: 73.41%
总股本: 5,809.21万
类型机构数股数
增持
28
191.21万
建仓
16
124.66万
减持
44
348.01万
平仓
33
480.48万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Non-Executive Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Other
Stephen Machatha
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
暂无数据
ALDX 简况
Aldeyra Therapeutics, Inc.(原名:Aldexa Therapeutics, Inc.)是一家生物技术公司。该公司主要活动包括筹集资金及研发活动。该公司从事鉴定和开发高醛相关疾病的治疗产品。该公司专注于开发用于治疗炎症引起的疾病以及天然病毒或称为醛类的炎性化学物质引起的先天性代谢紊乱的治疗产品。该公司已经开发各种用于隔离和允许醛类降解的醛阱小分子。该公司正在开发的醛阱NS2是一种用于治疗过敏性结膜炎和相关罕见过敏性眼部疾病、非感染性前葡萄膜炎、舍格伦-拉松综合征(SLS)和琥珀酸半醛脱氢酶缺乏症的候选产品。

微牛提供Aldeyra Therapeutics Inc(NASDAQ-ALDX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ALDX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALDX股票基本功能。